Increased use of testosterone supplementation among older men in recent years has caused concern about the safety of exogenous testosterone administration. New formulations and delivery mechanisms, increased direct-to-consumer marketing, and wider recognition of natural declines in testosterone levels in older age and chronic disease have all contributed to wider use of testosterone therapy, without strong evidence of benefit or assurance of safety in older men who are already at risk for morbidity and mortality. Recent randomized trials have suggested an increased risk of cardiovascular events, but the body of literature is still without conclusive evidence. Additional analyses of large populations are needed to better describe how testosterone therapy is used in real-world practice and assess the possibility that use of testosterone may increase risk of serious adverse events. We propose a large retrospective cohort study using healthcare and laboratory testing data from a large population of older men in the United States with Medicare or commercial insurance. We will also create a second cohort using clinical data from the United Kingdom's General Practice Research Database. We will study patterns of initiation relative to testosterone testing, and how prescribing has changed over time. We will use propensity score techniques to compare rates of cardiovascular events in testosterone users to those of non-users with comparable testosterone levels. We will examine the risk of bone fractures and prostate cancer as secondary outcomes. These effects will also be investigated in vulnerable subgroups (e.g. older age, chronic disease, varying levels of testosterone deficiency). We will study transient risk of acute events using a self-controlled case-crossover analysis. And finally, different testosterone delivery mechanisms (e.g. patch, gel, injections) will be compared to determine if there are differential risks among the different formulations. The results of this stuy will contribute important evidence to the growing, but yet inconclusive, body of literature surrounding the safety of exogenous testosterone use among older men.
Testosterone supplementation is increasingly used in older men, although the benefits and safety have not been well-established. This study will use insurance billing information and laboratory test results from the United States and medical records from the United Kingdom to determine if taking testosterone supplementation increases older men's risk of serious events such as heart attack, stroke, other cardiovascular diseases, bone fractures, and prostate cancer. This study will use modern statistical methods and novel study designs to provide accurate measures of the risk of these events in men supplementing testosterone.
|Li, Xiaojuan; Cole, Stephen R; Westreich, Daniel et al. (2018) Primary non-adherence and the new-user design. Pharmacoepidemiol Drug Saf 27:361-364|
|Layton, J Bradley; Li, Dongmei; Meier, Christoph R et al. (2018) Injection testosterone and adverse cardiovascular events: A case-crossover analysis. Clin Endocrinol (Oxf) 88:719-727|
|Layton, J Bradley; Kim, Yoonsang; Alexander, G Caleb et al. (2017) Association Between Direct-to-Consumer Advertising and Testosterone Testing and Initiation in the United States, 2009-2013. JAMA 317:1159-1166|
|Jirón, Marcela; Pate, Virginia; Hanson, Laura C et al. (2016) Trends in Prevalence and Determinants of Potentially Inappropriate Prescribing in the United States: 2007 to 2012. J Am Geriatr Soc 64:788-97|
|Gokhale, Mugdha; Buse, John B; Pate, Virginia et al. (2016) More realistic power estimation for new user, active comparator studies: an empirical example. Pharmacoepidemiol Drug Saf 25:462-6|
|Lund, Jennifer L; Sturmer, Til; Sanoff, Hanna K (2016) Comparative effectiveness of postoperative chemotherapy among older patients with non-metastatic rectal cancer treated with preoperative chemoradiotherapy. J Geriatr Oncol 7:176-86|
|Brookhart, M Alan; Freburger, Janet K; Ellis, Alan R et al. (2016) Comparative Short-term Safety of Sodium Ferric Gluconate Versus Iron Sucrose in Hemodialysis Patients. Am J Kidney Dis 67:119-27|
|Akizawa, Tadao; Kurita, Noriaki; Mizobuchi, Masahide et al. (2016) PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Sci Rep 6:19612|
|Lauffenburger, Julie C; Farley, Joel F; Gehi, Anil K et al. (2015) Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc 4:|
|McGrath, Leah J; Brookhart, M Alan (2015) On-label and off-label use of high-dose influenza vaccine in the United States, 2010-2012. Hum Vaccin Immunother 11:537-44|
Showing the most recent 10 out of 31 publications